Viking Therapeutics (NASDAQ:VKTX) Stock in Focus Ahead of Cash-Burn Scrutiny, Earnings Set for July 29
Viking heads into earnings week as its shares face downward pressure. The stock dropped 6.2% last week, with a 1.7% decrease on Friday.
Viking Therapeutics (NASDAQ:VKTX) stock maintains Phase 3 outlook despite 4.6% fall over the week
Viking Therapeutics, Inc. declined by 4.6% over the past week. Nonetheless, its initial cash-adjusted valuation remained 86% higher than that of Structure Therapeutics Inc..
Viking Therapeutics Stock Jumps as Obesity Drug Catalyst Nears
Viking Therapeutics shares rose sharply in Tuesday afternoon trading, climbing 6.0% to $34.30 as investors moved back into the clinical-stage biotech ahead of expected updates on its lead obesity-drug program. The Nasdaq-listed stock traded as high as $35.90 after opening at $31.76, with volume above 5.1 million shares.
Viking Therapeutics stock (VKTX) slips in premarket after 11% rally as Novo obesity-drug stumble hits tape
Viking Therapeutics slipped 0.5% to $34.30 ahead of Tuesday’s open, following an 11.1% surge the day before that took the stock to a $34.46 close. Monday’s range ran from $32.50 up to $35.73, with roughly 5.68 million shares traded.
Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names
Shares of Structure Therapeutics jumped roughly 7.5% Wednesday, as traders returned to small-cap obesity drugmakers. The stock climbed to $83.76, trading over 1 million shares.
Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals
Shares of Viking Therapeutics climbed roughly 11% on Wednesday, rising from a $30.44–$34.08 range to $34.06 by 1:09 p.m. EST. The move came amid renewed deal speculation in obesity treatments. CEO Brian Lian noted that interest was “broader than is visible” with more players “circling around the space.” Analysts put the potential market at $150 billion annually, and Pfizer’s $10 billion acquisition of Metsera last November has kept deal activity intense.
Pfizer stock slips as CEO says obesity cash-pay market is “almost like Viagra”
Pfizer Inc shares slipped about 0.7% to $25.10 Tuesday morning as investors digested the company’s latest obesity drug strategy unveiled at the J.P. Morgan Healthcare Conference in San Francisco. CEO Albert Bourla described the booming out-of-pocket weight-loss market as “almost like Viagra” now. Pfizer aims to launch 10 phase 3 trials for its Metsera obesity drugs by the end of 2026. The company has indicated it doesn’t expect revenue growth to resume until 2029.
Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing
Shares of Viking Therapeutics slid 9.9% to $31.93 in afternoon trading on Monday as obesity-drug stocks reacted to Novo Nordisk’s U.S. launch of a Wegovy weight-loss pill. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly fell 3.9% and the SPDR S&P Biotech ETF dropped 2.2%.
Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets
Structure Therapeutics shares fell 7.7% to $62.86 in afternoon trade on Monday, paring an earlier rally and marking another volatile session for the obesity-drug developer. The stock has ranged from $72.02 to $62.50 so far in the regular session.
Biggest Stock Losers Today: LEGN, MRVL, UL and More Slide as Wall Street Braces for a Fed Rate Cut (December 8, 2025)
Wall Street kicked off “Fed week” in a cautious mood on Monday, December 8, 2025. U.S. stock futures ticked slightly higher, with the S&P 500 hovering just below record territory as traders priced in an ~85–90% chance of another 25‑basis‑point rate cut at the Federal Reserve’s final meeting of the year. TechStock²+1
VKTX Stock Forecast 2025–2026: Can Viking Therapeutics’ Obesity Drug Pipeline Really Double the Share Price?
Viking Therapeutics has quietly become one of the most closely watched small-cap names in the weight-loss drug trade. As of the last trading session on Friday, December 5, 2025, VKTX closed at $38.55, giving the company a market capitalization of roughly $4.3–4.4 billion. Viking Therapeutics InvestorRoom+1
VKTX Stock Today, November 25, 2025: Can Viking Therapeutics Keep Riding the Obesity Drug Wave?
Viking Therapeutics heads into the Tuesday, November 25, 2025 session trading in the mid‑$30s, still digesting last week’s major milestone: the company has finished enrolling patients in its pivotal Phase 3 obesity trial VANQUISH‑1 ahead of schedule and above its original target. Viking Therapeutics InvestorRoom
Viking Therapeutics (VKTX) Pops as Canaccord Nudges Price Target to $107; Stifel Conference Buzz & Fresh ObesityWeek® Data — Nov. 12, 2025
Canaccord bumps target to $107. Before the open, Canaccord Genuity’s Edward Nash inched his VKTX target up by $1 to $107 and kept a Buy rating, framing Viking as a high‑quality obesity asset. The update follows Canaccord’s October initiation and comes as investors digest Stifel conference commentary and the latest clinical posters. StreetInsider.com+1
Viking Therapeutics (VKTX) on Nov. 11, 2025: Stifel Fireside Chat Today, Fresh VK2735 Obesity Data From ObesityWeek, and Phase 3 VANQUISH Progress
Viking Therapeutics, Inc. steps into the spotlight today with a scheduled fireside chat at the Stifel 2025 Healthcare Conference in New York. The appearance comes on the heels of new clinical analyses from ObesityWeek® 2025 and an October corporate update outlining steady Phase 3 progress for its lead obesity candidate, VK2735. Viking Therapeutics InvestorRoom
Viking Therapeutics (VKTX) Today — Nov 9, 2025: New Institutional Buying, Fresh Technical Levels, and Key Catalysts Ahead
Ethos Financial Group’s new position adds to a year when institutions already control roughly three‑quarters of the float. MarketBeat’s automated brief also captures the latest insider activity, and a blended “Moderate Buy” Street view. While 13F adds don’t guarantee direction, they often increase visibility ahead of catalysts. MarketBeat
Viking Therapeutics (VKTX) Rides Obesity Drug Wave: Stock Steadies as Analysts Eye Big Upside
Viking’s stock has stabilized in recent sessions, trading in the mid-$30s after a roller-coaster few months. It ended Friday at $33.53marketbeat.com, roughly flat on the week and not far from its intraday high of ~$36.80 on Thursdayir.vikingtherapeutics.com. This marks a dramatic recovery from mid-August, when VKTX plunged over 40% in one day following a crucial trial announcementts2.tech. Back then, Viking had unveiled results from a Phase 2 study of its oral obesity pill that missed investor expectations, triggering a sharp selloff. Since that rout, the stock has climbed back as optimism returns ahead of key catalysts. Heavy trading activity underscores the renewed interest – on Oct. 15, nearly 22,823 call options on VKTX traded, including a burst of bullish bets at the $50 January strikets2.tech. This elevated options volume suggests traders positioning for potential upside moves.
Wall Street Rebounds: PCE In‑Line, Tariff Shock, and Fed‑Cut Bets — What It All Means (Sept. 26, 2025)
1) The data that mattered: PCE & spendingMarkets exhaled as the Fed’s preferred inflation gauge arrived exactly as expected: headline PCE +0.3% m/m, core +0.2% m/m. Treasury yields drifted lower, with the 10‑yr near 4.18% and the 2‑yr around 3.65%, signaling relief that there was no upside shock. Futures ticked higher on the print. Reuters
TechStock² Updates
